Waltham, MA—Nova Biomedical announces the availability of Nova Primary, a rapid, accurate, easy to use, blood glucose laboratory analyzer. Nova Primary fills the need for a new glucose reference analyzer to replace the YSI STAT PLUS 2300 Glucose and L-Lactate analyzer (YSI,Inc., Yellow Springs, OH).
Manufacturers of blood glucose measuring devices and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, as of July 2021, YSI, Inc. will no longer support the analyzer, and its discontinuation has left a critical industry void. The Nova Primary analyzer fills that need. It will be available for sale in CE regulated countries as of January 2021. The Nova Primary was also submitted to the U.S. Food and Drug Administration (FDA) for 510(k) clearance in early December 2020 and is anticipated to receive clearance by the FDA in the first half of 2021.
Like the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 20-900 mg/dL. It uses a small, 25 microliter venous whole blood or plasma sample which is internally diluted like the YSI. Results are available in approximately 2 minutes. Nova Primary’s large color touchscreen display and intuitive, icon based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and number of samples remaining, eliminating the need for separate reagent bottles and daily monitoring of their levels. In clinical laboratory studies using venous whole blood and plasma it demonstrated excellent correlation to the YSI 2300 and is traceable to NIST glucose standards. The Nova Primary uses a comma delimited (.csv) format data output that can be downloaded via the integral USB data port. The analyzer measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm).
About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for a broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.